O	0	16	Cardioprotective
O	17	23	effect
O	24	26	of
B-intervention	27	37	Platycodon
I-intervention	38	50	grandiflorum
O	51	53	in
O	54	62	patients
O	63	67	with
O	68	73	early
O	74	80	breast
O	81	87	cancer
O	88	97	receiving
O	98	111	anthracycline
O	111	112	-
O	112	117	based
O	118	130	chemotherapy
O	130	131	:
O	132	137	study
O	138	146	protocol
O	147	150	for
O	151	152	a
O	153	163	randomized
O	164	174	controlled
O	175	180	trial
O	180	181	.

O	182	196	Anthracyclines
O	196	197	,
O	198	203	alone
O	204	206	or
O	207	209	in
O	210	221	combination
O	222	226	with
O	227	232	other
O	233	238	drugs
O	238	239	,
O	240	243	are
O	244	249	among
O	250	253	the
O	254	258	most
O	259	268	effective
O	269	285	chemotherapeutic
O	286	292	agents
O	293	295	to
O	296	301	treat
O	302	308	breast
O	309	315	cancer
O	316	320	both
O	321	323	in
O	324	327	the
O	328	336	adjuvant
O	337	340	and
O	341	352	neoadjuvant
O	353	360	setting
O	360	361	.

O	362	375	Unfortunately
O	375	376	,
O	377	390	anthracycline
O	390	391	-
O	391	401	associated
O	402	406	dose
O	406	407	-
O	407	416	dependent
O	417	431	cardiotoxicity
O	432	434	is
O	435	436	a
O	437	445	limiting
O	446	452	factor
O	453	455	in
O	456	464	clinical
O	465	468	use
O	468	469	.

O	470	479	Extensive
O	480	487	efforts
O	488	492	have
O	493	497	been
O	498	505	devoted
O	506	508	to
O	509	520	identifying
O	521	531	strategies
O	532	534	to
O	535	542	prevent
O	543	556	anthracycline
O	556	557	-
O	557	564	induced
O	565	579	cardiotoxicity
O	579	580	.

O	581	588	However
O	588	589	,
O	590	594	most
O	595	611	cardioprotective
O	612	618	agents
O	619	623	have
O	624	629	shown
O	630	636	little
O	637	643	effect
O	644	646	in
O	647	655	clinical
O	656	662	trials
O	662	663	.

O	664	670	Herbal
O	671	680	medicines
O	681	684	are
O	685	689	pure
O	689	690	,
O	691	698	natural
O	699	709	substances
O	710	714	that
O	715	719	have
O	720	724	been
O	725	729	used
O	730	733	for
O	734	743	centuries
O	744	746	in
O	747	751	many
O	752	761	countries
O	761	762	,
O	763	772	including
O	773	778	China
O	778	779	.

O	780	784	This
O	785	790	trial
O	791	795	aims
O	796	798	to
O	799	807	evaluate
O	808	811	the
O	812	828	cardioprotective
O	829	836	effects
O	837	840	and
O	841	847	safety
O	848	850	of
O	851	861	Platycodon
O	862	874	grandiflorum
O	875	883	granules
O	884	892	compared
O	893	895	to
O	896	903	placebo
O	904	912	granules
O	913	915	in
B-eligibility	916	924	patients
I-eligibility	925	929	with
I-eligibility	930	935	early
I-eligibility	936	942	breast
I-eligibility	943	949	cancer
I-eligibility	950	959	receiving
I-eligibility	960	973	anthracycline
I-eligibility	973	974	-
I-eligibility	974	979	based
I-eligibility	980	992	chemotherapy
O	992	993	.

O	994	998	This
O	999	1004	study
O	1005	1007	is
O	1008	1009	a
O	1010	1016	single
O	1016	1017	-
O	1017	1023	center
O	1023	1024	,
O	1025	1031	double
O	1031	1032	-
O	1032	1039	blinded
O	1039	1040	,
O	1041	1051	randomized
O	1051	1052	,
O	1053	1060	placebo
O	1060	1061	-
O	1061	1071	controlled
O	1071	1072	,
O	1073	1081	parallel
O	1081	1082	-
O	1082	1087	group
O	1088	1093	trial
O	1093	1094	.

O	1095	1096	A
O	1097	1102	total
O	1103	1105	of
B-total-participants	1106	1109	120
O	1110	1118	patients
O	1119	1123	will
O	1124	1126	be
O	1127	1135	randomly
O	1136	1145	allocated
O	1146	1148	in
O	1149	1150	a
O	1151	1152	1
O	1152	1153	:
O	1153	1154	1
O	1155	1160	ratio
O	1161	1163	to
O	1164	1171	receive
O	1172	1178	either
O	1179	1180	P
O	1180	1181	.
O	1182	1194	grandiflorum
O	1195	1203	granules
O	1204	1206	or
B-control	1207	1214	placebo
I-control	1215	1223	granules
O	1224	1229	twice
O	1230	1235	daily
O	1236	1239	for
O	1240	1242	12
O	1243	1248	weeks
O	1248	1249	.

O	1250	1253	The
O	1254	1261	primary
O	1262	1269	outcome
O	1270	1272	is
B-outcome-Measure	1273	1278	heart
I-outcome-Measure	1279	1286	failure
O	1287	1288	(
O	1288	1294	either
O	1295	1303	clinical
O	1304	1306	or
O	1307	1318	subclinical
O	1318	1319	)
O	1319	1320	.

O	1321	1324	The
O	1325	1334	secondary
O	1335	1343	outcomes
O	1344	1351	include
B-outcome-Measure	1352	1355	all
I-outcome-Measure	1355	1356	-
I-outcome-Measure	1356	1361	cause
I-outcome-Measure	1362	1371	mortality
O	1371	1372	,
B-outcome-Measure	1373	1380	cardiac
I-outcome-Measure	1381	1386	death
O	1386	1387	,
B-outcome-Measure	1388	1405	electrocardiogram
I-outcome-Measure	1406	1407	(
I-outcome-Measure	1407	1410	ECG
I-outcome-Measure	1410	1411	)
I-outcome-Measure	1412	1420	findings
O	1420	1421	,
B-outcome-Measure	1422	1426	left
I-outcome-Measure	1427	1438	ventricular
I-outcome-Measure	1439	1448	diastolic
I-outcome-Measure	1449	1457	function
O	1457	1458	,
B-outcome-Measure	1459	1471	longitudinal
I-outcome-Measure	1472	1480	systolic
I-outcome-Measure	1481	1487	strain
O	1488	1491	and
B-outcome-Measure	1492	1502	velocities
O	1503	1511	measured
O	1512	1514	by
O	1515	1521	tissue
O	1522	1529	Doppler
O	1530	1537	imaging
O	1537	1538	,
O	1539	1546	cardiac
O	1547	1557	biomarkers
O	1557	1558	,
O	1559	1563	such
O	1564	1566	as
O	1567	1575	troponin
O	1576	1577	I
O	1578	1579	(
O	1579	1582	TnI
O	1582	1583	)
O	1583	1584	,
O	1585	1590	brain
O	1591	1602	natriuretic
O	1603	1610	peptide
O	1611	1612	(
O	1612	1615	BNP
O	1615	1616	)
O	1616	1617	,
O	1618	1621	and
O	1622	1630	creatine
O	1631	1637	kinase
O	1638	1648	isoenzymes
O	1649	1650	(
O	1650	1652	CK
O	1652	1653	-
O	1653	1655	MB
O	1655	1656	)
O	1656	1657	.

O	1658	1669	Assessments
O	1670	1674	will
O	1675	1677	be
O	1678	1687	performed
O	1688	1690	at
O	1691	1699	baseline
O	1700	1701	(
O	1701	1707	before
O	1708	1721	randomization
O	1721	1722	)
O	1723	1726	and
O	1727	1728	3
O	1728	1729	,
O	1730	1731	6
O	1731	1732	,
O	1733	1734	9
O	1734	1735	,
O	1736	1738	12
O	1738	1739	,
O	1740	1742	16
O	1742	1743	,
O	1744	1747	and
O	1748	1750	20
O	1751	1756	weeks
O	1757	1762	after
O	1763	1776	randomization
O	1776	1777	.

O	1778	1782	This
O	1783	1787	will
O	1788	1790	be
O	1791	1794	the
O	1795	1800	first
O	1801	1809	clinical
O	1810	1815	trial
O	1816	1818	to
O	1819	1827	evaluate
O	1828	1831	the
B-outcome	1832	1848	cardioprotective
I-outcome	1849	1856	effects
I-outcome	1857	1860	and
I-outcome	1861	1867	safety
O	1868	1870	of
O	1871	1872	P
O	1872	1873	.
O	1874	1886	grandiflorum
O	1887	1889	in
O	1890	1898	patients
O	1899	1903	with
O	1904	1909	early
O	1910	1916	breast
O	1917	1923	cancer
O	1924	1933	receiving
O	1934	1947	anthracycline
O	1947	1948	-
O	1948	1953	based
O	1954	1966	chemotherapy
O	1966	1967	.

O	1968	1970	We
O	1971	1974	are
O	1975	1979	also
O	1980	1990	performing
O	1991	1995	this
O	1996	2001	trial
O	2002	2004	to
O	2005	2011	assess
O	2012	2015	the
O	2016	2027	feasibility
O	2028	2030	of
O	2031	2032	a
O	2033	2039	larger
O	2039	2040	-
O	2040	2045	scale
O	2046	2054	clinical
O	2055	2060	trial
O	2061	2063	in
O	2064	2067	the
O	2068	2074	future
O	2074	2075	.

O	2076	2083	Chinese
O	2084	2092	Clinical
O	2093	2098	Trial
O	2099	2107	Registry
O	2107	2108	,
O	2109	2115	ChiCTR
O	2115	2116	-
O	2116	2119	IPR
O	2119	2120	-
O	2120	2128	16009256
O	2129	2130	.

O	2131	2132	ï»¿
O	2132	2142	Registered
O	2143	2145	on
O	2146	2148	23
O	2149	2158	September
O	2159	2163	2016
O	2163	2164	.
